Header Logo

Connection

Alane Izu to Double-Blind Method

This is a "connection" page, showing publications Alane Izu has written about Double-Blind Method.
Connection Strength

0,163
  1. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
    View in: PubMed
    Score: 0,045
  2. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1885-1898.
    View in: PubMed
    Score: 0,044
  3. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 01 09; 397(10269):99-111.
    View in: PubMed
    Score: 0,043
  4. An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates. Vaccine. 1999 Aug 06; 17(23-24):2999-3006.
    View in: PubMed
    Score: 0,010
  5. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA. 1999 Jul 28; 282(4):331-40.
    View in: PubMed
    Score: 0,010
  6. Treatment of steroid-dependent asthma with recombinant interferon-gamma. Clin Exp Allergy. 1993 Sep; 23(9):785-90.
    View in: PubMed
    Score: 0,006
  7. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol. 1993 Feb; 28(2 Pt 1):189-97.
    View in: PubMed
    Score: 0,006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.